Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Uveal Melanoma 6Retinal Diseases 2Melanoma 2Macular Edema 2von Hippel-Lindau Disease 1Retinoblastoma 1Neurofibromatosis 1 1Neurofibroma 1Neoplasms 1Macular Degeneration 1Glaucoma, Neovascular 1Conjunctival Neoplasms 1Choroid Diseases 1

Interventions

mirdametinib 2tipifarnib 1talimogene laherparepvec 1peginterferon alfa-2b 1nilotinib 1binimetinib 1antineoplaston AS 2-1 1antineoplaston A10 1Vincristine 1Temozolomide 1Talaporfin 1Sirolimus 1Restraint, Physical 1Ranibizumab 1Radiosurgery 1Photochemotherapy 1Neurofibromin 1 1Mn-PyC3A 1Imatinib Mesylate 1Everolimus 1Elasticity Imaging Techniques 1Deoxycholic Acid 1Cryotherapy 1Celecoxib 1Aminolevulinic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neurofibroma × Ranibizumab × Clear all
NCT00657202 2016-07-07

Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1

Massachusetts General Hospital

Phase EARLY_PHASE1 Completed
11 enrolled
CNS

Neurofibroma, Neurofibromatosis 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡